Phase II Clinical Trial of Carboplatin, Ifosfamide, with Oral Mesna for Metastatic Breast Carcinoma

References

• Ahmann D L, Bisel H F, Hahn R G. Phase II clinical trial of ifosfamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 1974; 58(61)861–865
   PubMedGoogle Scholar
• Buzdar A U, Legha S S, Tashima C K, et al. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep 1979; 63(1)115–20
   PubMedGoogle Scholar
• Steger G G, Dittrich C, Schlappack O, et al. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer. J Cancer Res Clin Oncol 1988; 114: 602–604
   PubMed Web of Science ®Google Scholar
• Becher R, Hofeler H, Kloke O, et al. Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer. Semin Oncol 1989; 16((l)(Suppl3))56–59
   PubMedGoogle Scholar
• Paridaens R, Focan C, Michel J, et al. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. Cancer Chemother Pharmacol 1990; 26(suppl)63–65
   Google Scholar
• Ghavamzadeh A. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol 1990; 26(Suppl)66–68
   Google Scholar
• Hoffman W, Weidmann B, Migeod F, et al. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. Cancer Chemother Pharmacol 1990; 26(Suppl)69–70
   Google Scholar
• Schmid H, Kaufmann M, Grischke E-M, et al. Ifosfamide combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 1990; 26(Suppl)71–73
   PubMedGoogle Scholar
• Lange O F, Scheef W, Haase K D, et al. Palliative chemo-radio-therapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer: Results of a prospective multicenter trial. Cancer Chemother Pharmacol 1990; 26(Suppl)74–77
   Google Scholar
• Lange O F, Scheef W, Haase K D. Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases: A 5-year experience. Cancer Chemother Pharmacol 1990; 26(Suppl)78–80
   Google Scholar
• Bellmunt J, Morales S, Navarro M, et al. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother Pharmacol 1990; 26(Suppl)81–84
   Google Scholar
• Gad-El-Mawla N, Hamza M R, Zikri Z K, et al. Ifosfamide, methotrexate and 5-fluorouracil: Effective combination in resistant breast cancer. Cancer Chemother Pharmacol 1990; 26(Suppl)85–86
   Google Scholar
• Manegold C, Worst P, Bickel J, et al. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. Cancer Chemother Pharmacol 1990; 26(Suppl)87–90
   Google Scholar
• Sanchiz F, Milla A. High-dose ifosfamide and mesna in advanced breast cancer. Cancer Chemother Pharmacol 1990; 26(Suppl)91–92
   Google Scholar
• Langenbuch T, Mross K, Jonat W, et al. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. Cancer Chemother Pharmacol 1990; 26(Suppl)93–96
   PubMedGoogle Scholar
• Brock N, Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev 1983; 10(Suppl A)33–43
   PubMedGoogle Scholar
• Araujo C, Tessler J. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sul-phonate (mesna) to patints with inoperable lung cancer. Eur J Cancer Clin Oncol 1983; 19(2)195–201
   PubMedGoogle Scholar
• Sakurai M, Saijo N, Shinkai T, et al. The protective effect of 2-mercapto-ethane sulfonate (mesna) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 1986; 16(2)153–156
   PubMed Web of Science ®Google Scholar
• Shaw I C, Graham M I. Mesna–A short review. Cancer Treat Rev 1987; 14: 67–86
   PubMed Web of Science ®Google Scholar
• Shaw I C. Mesna and oxazaphosphorine cancer chemotherapy. Cancer Treat Rev 1987; 14: 359–364
   PubMed Web of Science ®Google Scholar
• Pratt C B, Goren M P. Ifosfamide/mesna and hematuria. Cancer Treat Rep 1987; 71(11)1124–1125
   PubMedGoogle Scholar
• Andriole G L, Sandlund J T, Miser J S, et al. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol 1987; 5(5)799–803
   PubMed Web of Science ®Google Scholar
• James C A, Mant T GK, Rogers H J. Phamacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 1987; 23: 561–568
   PubMed Web of Science ®Google Scholar
• Hilgard P, Pohl J. Oxazaphosphorine toxicity reduction by mesna. Cancer Treat Rev 1990; 17: 217–220
   PubMed Web of Science ®Google Scholar
• Williams S D, Munshi N, Einhorn L H, et al. Cyclophosphamide and ifosfamide: Role of uroprotective agents. Cancer Invest 1990; 8(2)269
   PubMedGoogle Scholar
• Yap H-Y, Salem P, Hortobagyi G N, et al. Phase II study of n'.s-dichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep 1978; 62: 405–408
   PubMedGoogle Scholar
• Forastiere A A, Hakes T B, Wittes J T, et al. Cisplatin in the treatment of metastatic breast carcinoma. Am J Clin Oncol 1982; 5: 243–247
   PubMed Web of Science ®Google Scholar
• Martino S, Samal B A, Singhakowinta A, et al. A phase II study of n.s-diammine-dichloroplatinum II for advanced breast cancer: Two dose schedules. J Cancer Res Clin Oncol 1984; 108: 354–356
   PubMed Web of Science ®Google Scholar
• Booth B W, Weiss R B, Korzun A H, et al. Phase II trial of carboplatin in advanced breast carcinoma: A Cancer and Leukemia Group B study. Cancer Treat Rep 1985; 69(7–8)919–920
   PubMedGoogle Scholar
• Wander H-E, Nagel G A. Carboplatin in advanced breast cancer. J Cancer Res Clin Oncol 1987; 114(Suppl)560
   Google Scholar
• Calvert A H, Newell D R, Gumbrell L A, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7(11)1748–1756
   PubMed Web of Science ®Google Scholar
• Jones M, Murrell R D, Shaw I C. Excretion of sodium 2-mercaptoethanesulphonate (mesna) in the urine of volunteers. Eur J Cancer Clin Oncol 1985; 21: 553–555
   PubMedGoogle Scholar